卵巢癌的基因治疗研究现状及展望

　　[17] Pongstaporn W, Rochanawutanon M, Wilailak S, et al. Genetic alterations in chromosome 10q24.3 and glutathione S-transferase omega 2 gene polymorphism in ovarian cancer [J]. J Exp Clin Cancer Res,2006,25(1):107-114.

　　[18] Novichkov EV, Votintsev AA. Ovarian cancer prognosis and expression of receptors to sex hormones and proliferative activity of tumor cells [J]. Arkh Patol,2006,68(2):10-13.

　　[19] Agarwal R, Kaye SB. Expression profiling and individualisation of treatment for ovarian cancer [J]. Curr Opin Pharmacol,2006,6(4):345-349.

　　[20] Wani AA, Sharma N, Shouche YS, et al. Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells [J]. Oncogene,2006,25(47):6336-6344.

　　[21] Bignotti E, Tassi RA, Calza S, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy [J]. Gynecol Oncol,2006,103(2):405-416.

　　[22] Menendez L, Walker D, Matyunina LV, et al. Identification of candidate methylation-responsive genes in ovarian cancer [J]. Mol Cancer,2007,(6):10-15.

　　[23] Haralambieva I, Iankov I, Hasegawa K, et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response [J]. Mol Ther,2007,15(3):588-597.

　　[24] Menczer J, Schreiber L, Czernobilsky B, et al. Is Her-2/neu expressed in nonepithelial ovarian malignancies?[J]. Am J Obstet Gynecol,2007, 196(1):79.e1-4.

　　[25] Psyrri A, Kountourakis P, Yu Z, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets [J]. Ann Oncol,2007,18(4):709-715.

上一页  [1] [2] [3] [4] [5]